NASDAQ
Chinook Therapeutics, Inc. (KDNY) has a free cash flow growth of -19.81% as of Friday, May 29, 2026. This represents a 11.75% increase compared to its 12-month average of -22.44%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.